Charles River Laboratories reported a strong fourth quarter with revenue of $691.1 million, a 14.9% increase year-over-year. GAAP EPS was $1.61 and non-GAAP EPS was $2.01. The company's performance was driven by the breadth of its early-stage portfolio and investments in scientific capabilities.
Fourth-quarter revenue increased by 14.9% to $691.1 million.
Organic revenue growth was 7.4%, driven by all three business segments.
GAAP earnings per share were $1.61, a 33.1% increase year-over-year.
Non-GAAP earnings per share were $2.01, a 26.4% increase year-over-year.
The Company is providing revenue, earnings per share, and free cash flow guidance for 2020. Earnings per share in 2020 are expected to benefit from higher revenue, driven primarily by continued robust client demand, and meaningful operating margin improvement.
Visualization of income flow from segment revenue to net income